A Phase 2 interventional study of Health Education and Subspecialty clinic referral in HIV-1-infection, Coronary Microvascular Dysfunction and Metabolic Disease, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to female participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Metabolic Diseases by Massachusetts General Hospital — 3 open to participants now, 3 under way, none of them phase 3. Metabolic Diseases · Massachusetts General Hospital.
Among the 10 studies in Metabolic Diseases by Massachusetts General Hospital, this one is the only one that started in 2025, is the only one in phase 2, and was the 9th registered.
765 studies on the registry are indexed under Metabolic Diseases; 194 are open to participants now.
Browse Metabolic Diseases studies →3 of the 10 studies in Metabolic Diseases by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18–65 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
Of the 135 Metabolic Diseases studies recruiting now, 47 (35%) set no upper age limit and 64 (47%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 45 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 50 across 524 interventional studies indexed under Metabolic Diseases.
Median enrollment 41 across the 8 interventional studies, 60 across the 2 observational. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
1 of the studies in Metabolic Diseases by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06003153Massachusetts General HospitalGLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Metabolic Diseases by Massachusetts General Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed. We are conducting a study randomizing women with HIV and either diabetes, chronic kidney disease, or both to health education alone or to health education plus referral to see either an Endocrinologist or a Nephrologist in a subspecialty clinic for consideration of treatment with medication in a class known as sodium glucose transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors are clinically approved for use in patients with diabetes or chronic kidney disease but have been shown to be underutilized in people with HIV. One of our key analytic aims will be to test if SGLT2 inhibitor therapy results in improved blood flow through the large and small coronary arteries among women with HIV and either diabetes, chronic kidney disease, or both but who have no history of myocardial infarction. A second aim will be to test if subspecialty clinic referral (with or without SGLT2 inhibitor therapy prescription) results in improved blood flow through the large and small coronary arteries among the same group.
Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed. We are conducting a study randomizing women with HIV and either diabetes, chronic kidney disease, or both to health education alone or to health education plus referral to see either an Endocrinologist or a Nephrologist in a subspecialty clinic for consideration of treatment with medication in a class known as sodium glucose transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors are clinically approved for use in patients with diabetes or chronic kidney disease but have been shown to be underutilized in people with HIV. Prior to randomization, to confirm eligibility, participants will have undergone history, physical, lab tests, and cardiac positron emission tomography/computed tomography (PET/CT) scanning to confirm that there is a measure of impairment in stimulated blood flow through the large and small arteries of the heart. Randomized participants in both groups will be followed for 6 months and then will undergo repeat history, physical, laboratory testing, and repeat cardiac PET/CT scanning. One of our key analytic aims will be to test if SGLT2 inhibitor therapy results in improved blood flow through the large and small coronary arteries among women with HIV and either diabetes, chronic kidney disease, or both but who have no history of myocardial infarction. A second aim will be to test if subspecialty clinic referral (with or without SGLT2 inhibitor therapy prescription) results in improved blood flow through the large and small coronary arteries among the same group. We will also investigate effects of SGLT inhibitor therapy (and, separately, of subspecialty clinic referral) on fat tissue around the heart, as well as on blood and urine-based markers of metabolic disease and inflammation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to this study arm will receive health education and will be referred to establish clinical care in either the MGH Lipid and Metabolism Clinic or the MGH Renal Clinic for consideration of SGLT2 inhibitor therapy. By study design (inclusion criteria), participants will have a clinical indication for SGLT2 inhibitor therapy (either diabetes or chronic kidney disease). SGLT2 inhibitor therapy (e.g. empagliflozin 10 mg by mouth daily or dapagliflozin 10 mg by mouth daily) may or may not be prescribed by the subspecialty clinician as part of routine clinical care, according to the clinician's clinical judgement. Participants will also receive health education.
Other: Health Education
Participants randomized to this study arm will receive health education alone.
Other: Health Education · Other: Subspecialty clinic referral
Health Education
This intervention will entail referred to establish clinical care in either the MGH Lipid and Metabolism Clinic or the MGH Renal Clinic for consideration of SGLT2 inhibitor therapy. SGLT2 inhibitor therapy (e.g. empagliflozin 10 mg by mouth daily or dapagliflozin 10 mg by mouth daily) may or may not be prescribed by the subspecialty clinician as part of routine clinical care, according to the clinician's clinical judgement.
Coronary Flow Reserve
Change in coronary flow reserve by cardiac positron emission tomography
Time frame: 24 weeks
Ectopic Adipose Tissue
Change in ectopic adipose tissue reserve by cardiac computed tomography
Time frame: 24 weeks
Kidney-related biomarkers
Urine and serum biomarkers related to kidney health and disease
Time frame: 24 weeks
Metabolic biomarkers
Urine and serum biomarkers relating to metabolism (including glucose and lipid metabolism)
Time frame: 24 weeks
Immune/inflammatory biomarkers
Urine and serum biomarkers relating to inflammation and immune activation
Time frame: 24 weeks
HIV-specific parameters
Serum variables relating to HIV disease (such as HIV-1 viral load, CD4 T cell count, CD8 T cell count)
Time frame: 24 weeks
Plan to share: Yes — Plans are for IPD to be shared to the NIH BioLINCC data repository.
Supporting information: Study protocol, Informed consent form
Time frame: Data will be made available 12 months after study completion and will remain available for a duration of time consonant with NIH policies.
Access criteria: Access criteria are as per the NIH BioLINCC data repository.
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Mar 2029, 47 months after the start.
Of 27 phase 2 interventional studies under Metabolic Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 58. This study's planned 47 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →